Health Choice Alliance, LLC v. Eli Lilly and Company, Inc. et al

  1. September 30, 2019

    DOJ Wins Bids To End FCA Suits Targeting Eli Lilly, Bayer

    The federal government's interest in conserving resources is a good enough reason for the U.S. Department of Justice to torpedo whistleblower False Claims Act suits, a Texas federal judge has ruled in axing FCA cases accusing Eli Lilly and Bayer of funneling kickbacks to doctors.

  2. May 17, 2019

    Texas Judge Backs Broad DOJ Authority To End FCA Suits

    A Texas federal judge on Thursday recommended the dismissal of False Claims Act suits accusing Eli Lilly and Bayer of providing kickbacks to doctors in the form of various assistance services, saying the U.S. Department of Justice has "virtually unfettered" dismissal authority in whistleblower FCA cases.

  3. April 17, 2019

    DOJ Dismissal Power Looking Wobbly In FCA Cases

    The U.S. Department of Justice's newly launched campaign to shrink its False Claims Act docket has hit surprising turbulence as federal judges scrutinize the DOJ's willingness to look the other way on alleged fraud and its disparagement of a company that specializes in bringing FCA cases.

  4. January 23, 2019

    FCA Co. Torches DOJ Effort To Scuttle Suits

    A company that specializes in bringing False Claims Act cases has launched a scorched-earth attack on the U.S. Department of Justice for seeking dismissal of nearly a dozen suits it filed, accusing the DOJ of trying to "legalize certain kickbacks" to doctors from drugmakers.

  5. December 18, 2018

    DOJ Aims Torpedo At 11 FCA Kickback Suits

    In a striking development, the U.S. Department of Justice is seeking to terminate 11 False Claims Act cases involving a new theory that patient assistance services supplied by drugmakers are unlawful kickbacks.

  6. August 14, 2018

    Drug Kickback Suit Against Eli Lilly Dismissed For Now

    A Texas federal judge gave Eli Lilly and Co. and four health care companies a reprieve from a whistleblower lawsuit alleging they conspired to offer kickbacks to boost prescriptions of insulin and osteoporosis drugs, finding that a health care research organization's allegations were too vague but leaving the door open for the group to try again.